Search Bar & Filters
Found 5 Actively Recruiting clinical trials
Actively Recruiting
Healthy Volunteer
Researchers are evaluating SYX-5219 in a multi-part, first-in-human Phase 1 study involving healthy volunteers and people with moderate to severe atopic dermatitis AD. The study aims to determine the safety, tolerability, and levels of SYX-5219 in blood and urine when given in different dosing schedules. This includes single ascending doses, multiple ascending doses, and multiple dose administrations in participants with AD. The study has three parts Part 1 involves single ascending doses and a food effect evaluation in healthy volunteers, with doses given once on Day 1 and again after a washout period. Part 2 involves multiple ascending doses given once or twice daily to healthy volunteers over a defined period. Part 3 enrolls participants with AD who receive SYX-5219 or placebo twice daily for up to 42 days. Each part includes randomization and placebo control to compare effects. Participants will undergo safety and exploratory efficacy assessments during and after treatment, including monitoring adverse events up to 10 days after dosing in Part 1, 14 days after the last dose in Part 2, and up to Day 56 in Part 3. Blood and urine samples are collected at multiple timepoints to measure SYX-5219 levels. The study includes follow-up visits to monitor participant health and drug effects for several weeks after treatment ends.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of increasing doses of WVE-007, a stereopure siRNA oligonucleotide, given by subcutaneous injection to adults living with overweight or obesity. The study is conducted in two parts Part A, a single ascending dose study in adults with overweight or mild obesity, and Part B, a repeat dose study in adults with obesity, including those with or without Type 2 Diabetes T2D. Part B also includes groups receiving both WVE-007 and tirzepatide to assess combined effects. Participants are randomly assigned to one of several groups receiving different doses of WVE-007 or placebo. Part A includes doses 1 through 5, while Part B evaluates doses 4 through 7 some groups in Part B also receive weekly tirzepatide alongside WVE-007 or placebo. The study uses a triple-blind design to compare the effects of these treatments. The treatment periods last up to 253 days in Part B and 169 days in Part A, with careful dose escalation and monitoring. During the study, participants undergo regular safety assessments to monitor adverse events from the first day through study end. Researchers measure drug levels in plasma and observe changes in serum activin E over time. Participants will have clinical exams, laboratory tests, and pharmacokinetic and pharmacodynamic evaluations. The study runs until December 2027, allowing long-term follow-up of safety and biological effects.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating MTX325 as a potential disease-modifying treatment for Parkinsons Disease PD in this multi-part Phase 1 trial. The study includes healthy volunteers and patients with mild to moderate and early-stage PD, aiming to assess safety, tolerability, pharmacokinetics, brain biodistribution, and the effects of food on the drug. Parts 1 to 4, involving single and multiple ascending doses in healthy adults including elderly participants, are complete, with Part 5 focusing on multiple doses in PD patients currently ongoing. Participants receive oral capsules of MTX325 at various doses or matching placebo capsules depending on the study part. The trial includes a PET biodistribution study with radiolabeled MTX325 in healthy volunteers. Parts 1 through 4 evaluated single ascending doses, multiple ascending doses, elderly cohorts, and PET biodistribution, while Part 5 involves multiple dosing in PD patients. The study uses a randomized, parallel design without masking. Participants undergo screening including MRI and PET imaging, laboratory testing, ECG, and cognitive assessments before dosing. Safety and tolerability are monitored up to 28 days post-dose. The study involves repeated visits for assessments and dosing, with adherence to scheduled visits and protocols required. Researchers measure adverse events, brain drug distribution, and pharmacokinetics to evaluate MTX325s potential as a PD treatment. The total study duration varies by part, with ongoing follow-up to assess safety and drug effects.
Actively Recruiting
Researchers are evaluating IMVT-1402, a drug being studied for adults with Graves disease GD who remain hyperthyroid despite antithyroid drug treatment. This Phase 2b, randomized, double-blind, placebo-controlled study aims to assess the drugs efficacy, safety, and tolerability in a global, multi-center setting. Participants are assigned to receive one of two doses of IMVT-1402 or a placebo for 26 weeks. The study compares these groups to see how well IMVT-1402 helps participants become euthyroid normal thyroid function and stop antithyroid drugs. The two doses are given over the same 26-week period, with monitoring at several time points. During the trial, participants will undergo regular evaluations including thyroid hormone measurements such as triiodothyronine T3 and free thyroxine FT4. Researchers will measure how many participants achieve normal thyroid hormone levels and are off antithyroid drugs by Week 26. Safety and tolerability are also monitored throughout. The main outcome is the percentage of participants who are euthyroid and off antithyroid drugs at Week 26, with follow-up assessments planned for this duration.
Actively Recruiting
Healthy Volunteer
This research aims to identify if a new biomarker related to blood clot risk, called endothelial derived extracellular vesicles, along with changes in blood clotting time, can predict which patients with a Transient Ischemic Attack TIA are most likely to have a stroke. The study focuses on TIA patients, as over 25% of ischemic stroke cases occur in people who previously had a TIA. Stroke is a leading cause of disability, and preventing strokes in high-risk patients is a national health priority. The study will follow 300 participants over 12 months, divided into four groups healthy individuals without stroke or TIA history people referred to TIA clinics but found not to have TIA patients confirmed with TIA who did not have a stroke within 12 months and patients with TIA who did have a stroke within 12 months. Researchers will monitor and compare changes in extracellular vesicle levels and prothrombin time in these groups to assess stroke risk. Participants will undergo blood tests to measure the biomarker and clotting time, with follow-up over three years to observe changes. The study collects clinical information and imaging results to confirm stroke or TIA diagnosis. Researchers will also track patient diet status and medication use. The main outcomes are changes in the extracellular vesicles and prothrombin time, which may help identify those at highest risk for stroke after TIA.